Navigation Links
Lilly Reports First-Quarter 2011 Results
Date:4/18/2011

$1.13(16)%In-process research and development charges

  associated with Boehringer Ingelheim

  collaboration (2011) and Acrux licensing

  agreement (2010).23.03Asset impairments and restructuring charges

.06.02Earnings per share (non-GAAP)  $1.24$1.185%U.S. Health Care Reform Impact

U.S. health care reform reduced first-quarters 2011 and 2010 earnings per share by approximately $.10 and $.12 per share, respectively, on both a reported and non-GAAP basis. For the first quarter of 2011, U.S. health care reform reduced revenue by approximately $90 million due to higher rebates and subsidies, and increased administrative expenses by approximately $45 million related to the mandatory pharmaceutical manufacturers fee. For the first quarter of 2010, U.S. health care reform reduced revenue by approximately $60 million due to higher rebates, and increased tax expense by $85.1 million due to the imposition of tax on the prescription drug subsidy of the company's retiree health plan.(Dollars in millions)First Quarter

% Change

Over/(Under)20112010

2010Zyprexa

$1,281.9$1,215.06%Cymbalta®

908.8803.213%Alimta®

579.9527.410%Humalog®

525.4506.44%Cialis®

434.4408.36%Humulin®

289.8257.812%Evista®

266.1241.610%Forteo®

216.1194.511%Gemzar®

156.1287.8(46)%Strattera®

138.7146.4(5)%Animal Health

369.8289.628%Total Revenue

$5,839.2$5,485.56%Zyprexa

In the first quarter of 2011, Zyprexa sales totaled $1.282 billion, an increase of 6 percent compared with the first quarter of 2010.  U.S. sales of Zyprexa increased 2 percent to $597.1 million, driven by higher prices, partially offset by lower volume. Zyprexa sales in international markets increased 8 percent, to $684.8 million, driven primarily by higher volume, and to a lesser extent the favorable impact of foreign exchang
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
3. Lilly and Glenmark Pharmaceuticals Announce License Agreement
4. Lilly Receives NCQA Design Certification for Depression Care Management Program
5. JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers
6. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
7. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
8. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
9. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
10. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
11. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... and HOUSTON, TX , ... the "Company") (TSX-V: EPI) and Bloom Burton & Co. ... from voluntary contractual lock-up (the "Lock-Up") 2,353,130 common shares ... Common Shares originally subject to the Lock-Up. Of the ... be free trading immediately upon release from the Lock-Up ...
(Date:2/27/2015)... -- Boston Scientific Corporation (NYSE: BSX ) is ... Conference on March 10 in Miami Beach ... vice president and chief financial officer, and Susie ... a 25-minute question and answer session regarding the company ... Following a 5-minute break, a question and answer session ...
(Date:2/27/2015)... Feb. 27, 2015   Synageva BioPharma Corp. ... company developing therapeutic products for rare diseases, joins ... European Organisation for Rare Diseases™ (EURORDIS™), The Global ... observing Rare Disease Day. On the ... industry, and other participants conduct special events to ...
Breaking Medicine Technology:ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 2ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 3ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 4Boston Scientific to Participate in the Barclays 2015 Annual Healthcare Conference 2Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 2Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 3Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 4Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 5Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 6
... Nov. 2, 2010 /PRNewswire-Asia-FirstCall/ -- BMP Sunstone Corporation (Nasdaq: ... today announced that the Company plans to release third ... after the market closes. The Company will ... November 9, 2010 to discuss its results.  Listeners may ...
... 2, 2010 Arlington Medical Resources (AMR), ... and diagnostic imaging industries, finds that the leading driver ... States is activity against key drug-resistant pathogens. Such pathogens ... and multidrug-resistant Steptococcus pneumonia. "Nosocomial ...
Cached Medicine Technology:BMP Sunstone to Report Third Quarter 2010 Financial Results 2Activity Against Key Drug-Resistant Pathogens is the Most Important Attribute Influencing Surveyed Physicians' Antibiotic Selection for Nosocomial Pneumonia in the U.S. 2
(Date:2/27/2015)... Laguna Hills, CA (PRWEB) February 27, 2015 ... has been chosen as their Sage ERP Document Management ... ERP, Sage 300 ERP, Sage CRM and other complimentary ... ADSS Global have worked side-by-side for many years to ... their Sage ERP applications. , “We are thrilled ...
(Date:2/27/2015)... In New York City, a Brooklyn dentist is ... care from his Sheepshead Bay­neighborhood practice. Dr. Leonard ... Heart, and will be hosting a charity event on ... are in need of fillings, extractions, or professional dental ... high­quality service of Dr. Umanoff's practice on the Dentistry ...
(Date:2/27/2015)... February 27, 2015 The federal court ... that allege use of the statin medication can increase ... issued a new order pertaining discovery in the cases ... Liebhard LLP comments. The Order, which was issued in ... February 25th, directs the parties to schedule certain witness ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 According to ... General Hospital on June 25, 2013 and underwent a ... stomach through her mouth. Because the duodenoscope allegedly ... with the antibiotic-resistant “superbug” carbapenem-resistant Enterobacteriaceae (CRE). ... Court of Cook County on behalf of Ms. Pirolli ...
(Date:2/27/2015)... 2015 Adding to its rich ... Benedict Advertising & Marketing has added Sedation Systems ... company’s patented NITROUSEAL® N20 closed mask and breathing ... sedation. , Sedation Systems, http://www.sedationsystems.com is ... new level, though it focuses primarily on pediatric ...
Breaking Medicine News(10 mins):Health News:Altec Announces 2014 Sage ERP Document Management Partner of the Year Award Recipient 2Health News:Dr. Umanoff Unites with Dentistry from the Heart to Provide Community with Charitable Dental Care 2Health News:Dr. Umanoff Unites with Dentistry from the Heart to Provide Community with Charitable Dental Care 3Health News:Federal Lipitor Litigation Issues New Order Pertaining to Discovery in Bellwether Cases, Bernstein Liebhard LLP Comments 2Health News:Federal Lipitor Litigation Issues New Order Pertaining to Discovery in Bellwether Cases, Bernstein Liebhard LLP Comments 3Health News:Lawsuit Alleges Blame on Scope Manufacturer for "Superbug" Outbreak 2Health News:Benedict Advertising & Marketing Signs Sedation Systems 2
... (CCC) have selected Turning The Tide Together as the theme ... be held in Washington, D.C. from 22 27 July ... moment in time, emphasizing that the AIDS epidemic has reached ... in HIV treatment and biomedical prevention, the momentum for a ...
... TUESDAY, Sept. 20 (HealthDay News) -- People affected by ... without it to develop schizophrenia, and those with schizophrenia ... than people who are not schizophrenic, a new study ... between the two conditions may be due to genetic, ...
... Mitchell, IGB faculty member in the Mining Microbial Genomes ... the Department of Chemistry, is a recipient of the ... The award recognizes bold ideas from some of the ... award, given over a period of five years, supports ...
... about cancer and cancer treatments can feel like learning a ... to understand their treatment options, and the risks and benefits ... death decisions that may affect their survival and they need ... tests can be serious. Patients need to know what kind ...
... An analysis of more than 30,000 cancer patients has ... doctors may realize, causing additional hospitalizations and driving up the ... Duke Cancer Institute researcher. The study, which will be ... in Stockholm, found that as many as one in five ...
... method of family planning developed by researchers from the ... effectively meets the needs of users that they continue to ... that women who follow the Standard Days Method, are likely ... Results of the large, multi-country study of 1659 women appear ...
Cached Medicine News:Health News:Turning the Tide Together: AIDS 2012 theme selected 2Health News:Researchers Find Link Between Epilepsy, Schizophrenia Risk 2Health News:10 ways to make better decisions about cancer care 2Health News:10 ways to make better decisions about cancer care 3Health News:Costly blood clots more common than expected among cancer patients 2Health News:Long-term effectiveness of new family planning method shown in study 2
1.7/2.2 mm Delta System resorbable implant technology merges science and simplicity for a superior craniomaxillofacial surgery product. The system consists of resorbable bone plates and screws fabric...
... A-scan Sonomed-315 is intended for visualization of ... of midline shifts in the brain, evaluation ... easy to use, the Sonomed-315 offers quick ... mode allows to identify the anatomic structures ...
... a scaleable device that works ... platelet plasma or buffy coat. ... coat must be prepared independently ... Starting volume and concentration factor ...
The Ultrafoam Collagen Sponge is indicated in all surgical procedures as an adjunct to hemostasis when control by ligature or conventional procedures are ineffective or impractical....
Medicine Products: